Record Information |
---|
Version | 5.0 |
---|
Status | Detected and Quantified |
---|
Creation Date | 2006-10-16 11:45:18 UTC |
---|
Update Date | 2022-03-07 02:49:25 UTC |
---|
HMDB ID | HMDB0005000 |
---|
Secondary Accession Numbers | |
---|
Metabolite Identification |
---|
Common Name | Loratadine |
---|
Description | desloratadine is available off the shelf in Canada); Loratadine is a tricyclic antihistamine, which has a selective and peripheral H1-antagonist action. It has a long-lasting effect and does not normally cause drowsiness because it does not readily enter the central nervous system; An antiviral that is used in the prophylactic or symptomatic treatment of influenza A. It is also used as an antiparkinsonian agent, to treat extrapyramidal reactions, and for postherpetic neuralgia. The mechanisms of its effects in movement disorders are not well understood but probably reflect an increase in synthesis and release of dopamine, with perhaps some inhibition of dopamine uptake; Loratadine is a drug used to treat allergies. It is marketed by Schering-Plough under several trade names such as Claritin, Clarityn or Claratyne depending on the market, by Lek as Lomilan and by Wyeth as Alavert. It is also available as a generic; Loratadine is a drug used to treat allergies. It is marketed by Schering-Plough under several trade names such as Claritin, Clarityn or Claratyne depending on the market, by Lek as Lomilan and by Wyeth as Alavert. It is also available as a generic. Its active metabolite, desloratadine, is also on the market, though loratadine itself is the only drug of its class available over the counter (at least in the U.S. as of 2005. Loratadine is available off the shelf in the UK. |
---|
Structure | CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2 InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3 |
---|
Synonyms | Value | Source |
---|
4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester | ChEBI | Aerotina | ChEBI | Alarin | ChEBI | Alavert | ChEBI | Alerpriv | ChEBI | Allerclear | ChEBI | Civeran | ChEBI | Claratyne | ChEBI | Claritin | ChEBI | Loracert | ChEBI | Loradamed | ChEBI | Loradex | ChEBI | Lorastine | ChEBI | Loratadina | ChEBI | Loratadinum | ChEBI | Loratyne | ChEBI | Wal-itin | ChEBI | 4-(8-Chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene)-1-piperidinecarboxylate ethyl ester | Generator | 4-(8-Chloro-5,6-dihydro-11H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic acid ethyl ester | MeSH | Clarium | MeSH | Amantadine | HMDB | Anhissen | HMDB | Bonalerg | HMDB | Claritine | HMDB | Clarityn | HMDB | Clarityne | HMDB | Cronopen | HMDB | Flonidan | HMDB | Fristamin | HMDB | Histaloran | HMDB | Klaritin | HMDB | Lertamine | HMDB | Lisino | HMDB | Loranox | HMDB | Loratidine | HMDB | Loratadine wyeth brand | MeSH, HMDB | Wyeth brand OF loratadine | MeSH, HMDB |
|
---|
Chemical Formula | C22H23ClN2O2 |
---|
Average Molecular Weight | 382.883 |
---|
Monoisotopic Molecular Weight | 382.144805697 |
---|
IUPAC Name | ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate |
---|
Traditional Name | ethyl 4-{13-chloro-4-azatricyclo[9.4.0.0^{3,8}]pentadeca-1(11),3(8),4,6,12,14-hexaen-2-ylidene}piperidine-1-carboxylate |
---|
CAS Registry Number | 79794-75-5 |
---|
SMILES | CCOC(=O)N1CCC(CC1)=C1C2=C(CCC3=C1N=CC=C3)C=C(Cl)C=C2 |
---|
InChI Identifier | InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3 |
---|
InChI Key | JCCNYMKQOSZNPW-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | Belongs to the class of organic compounds known as benzocycloheptapyridines. These are aromatic compounds containing a benzene ring and a pyridine ring fused to a seven membered carbocycle. |
---|
Kingdom | Organic compounds |
---|
Super Class | Organoheterocyclic compounds |
---|
Class | Benzocycloheptapyridines |
---|
Sub Class | Not Available |
---|
Direct Parent | Benzocycloheptapyridines |
---|
Alternative Parents | |
---|
Substituents | - Benzocycloheptapyridine
- Piperidinecarboxylic acid
- Aryl chloride
- Aryl halide
- Piperidine
- Pyridine
- Benzenoid
- Heteroaromatic compound
- Carbamic acid ester
- Carbonic acid derivative
- Azacycle
- Hydrocarbon derivative
- Organic oxide
- Organooxygen compound
- Organonitrogen compound
- Organochloride
- Organohalogen compound
- Carbonyl group
- Organopnictogen compound
- Organic oxygen compound
- Organic nitrogen compound
- Aromatic heteropolycyclic compound
|
---|
Molecular Framework | Aromatic heteropolycyclic compounds |
---|
External Descriptors | Not Available |
---|
Ontology |
---|
Physiological effect | |
---|
Disposition | |
---|
Process | |
---|
Role | |
---|
Physical Properties |
---|
State | Solid |
---|
Experimental Molecular Properties | Property | Value | Reference |
---|
Melting Point | 134 - 136 °C | Not Available | Boiling Point | Not Available | Not Available | Water Solubility | Not Available | Not Available | LogP | 5.20 | SANGSTER (1994) |
|
---|
Experimental Chromatographic Properties | Experimental Collision Cross Sections |
---|
Predicted Molecular Properties | |
---|
Predicted Chromatographic Properties | Predicted Collision Cross SectionsPredicted Kovats Retention IndicesUnderivatized |
---|
Spectra |
---|
| GC-MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - Loratadine GC-MS (Non-derivatized) - 70eV, Positive | splash10-004i-6059000000-3d596b5ab5499c4089ca | 2017-09-01 | Wishart Lab | View Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - Loratadine GC-MS (Non-derivatized) - 70eV, Positive | Not Available | 2021-10-12 | Wishart Lab | View Spectrum |
MS/MS SpectraSpectrum Type | Description | Splash Key | Deposition Date | Source | View |
---|
Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine LC-ESI-qTof , Positive-QTOF | splash10-001r-0039000000-928ed9c6b46ba83ebe20 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine , positive-QTOF | splash10-001r-1279000000-1c522c39e53b6bbfb9aa | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine , positive-QTOF | splash10-001r-0039000000-928ed9c6b46ba83ebe20 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine , positive-QTOF | splash10-067r-1292000000-3869907bd01f927b6f22 | 2017-09-14 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 75V, Positive-QTOF | splash10-067i-0090000000-9bcbcadeda0bf07da702 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 90V, Positive-QTOF | splash10-0frx-0090000000-2f8b7b5acca254e4cb20 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 40V, Positive-QTOF | splash10-067i-0090000000-b247e61957d933538341 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 10V, Positive-QTOF | splash10-001i-0009000000-dce8adc02434b224d589 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 10V, Positive-QTOF | splash10-001i-0009000000-7d2b8c3f5f87f99fcf7a | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 60V, Positive-QTOF | splash10-0api-0090000000-8419cf3b0c888e52c95b | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 45V, Positive-QTOF | splash10-067r-0093000000-956a3618f6003ae45808 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 40V, Positive-QTOF | splash10-067i-0090000000-b62a29b4d6252b26f2bf | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 20V, Positive-QTOF | splash10-001r-0009000000-d32917132c3359e65572 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 20V, Positive-QTOF | splash10-0019-0019000000-1acbfc6c05c2d600a966 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 15V, Positive-QTOF | splash10-001i-0009000000-4558440f48e82bf6eefb | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 30V, Positive-QTOF | splash10-0019-0009000000-ea1b61e9df959d6680c2 | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 75V, Positive-QTOF | splash10-067i-0090000000-cf7d75b43a3c2c0f0d1e | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 50V, Positive-QTOF | splash10-066r-0090000000-c5d1377bb7159732d4db | 2021-09-20 | HMDB team, MONA | View Spectrum | Experimental LC-MS/MS | LC-MS/MS Spectrum - Loratadine 40V, Positive-QTOF | splash10-015i-0092000000-9bb7dcefe2f2f4f14bfd | 2021-09-20 | HMDB team, MONA | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 10V, Positive-QTOF | splash10-001i-0009000000-41dd9857a0206fa0f4e8 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 20V, Positive-QTOF | splash10-06ri-1029000000-0c5a179194107a35af3e | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 40V, Positive-QTOF | splash10-015c-2091000000-fb50d1834a9a1d8d6c90 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 10V, Negative-QTOF | splash10-001r-1009000000-78af7865fc3439c125c5 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 20V, Negative-QTOF | splash10-000i-2009000000-df88de530c8ff41c69f4 | 2016-08-03 | Wishart Lab | View Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - Loratadine 40V, Negative-QTOF | splash10-0adl-7069000000-a5804bf835988dc83d2a | 2016-08-03 | Wishart Lab | View Spectrum |
NMR SpectraSpectrum Type | Description | Deposition Date | Source | View |
---|
Experimental 2D NMR | [1H, 13C]-HSQC NMR Spectrum (2D, 600 MHz, H2O, experimental) | 2012-12-05 | Wishart Lab | View Spectrum |
|
---|
Biological Properties |
---|
Cellular Locations | - Membrane (predicted from logP)
|
---|
Biospecimen Locations | |
---|
Tissue Locations | |
---|
Pathways | |
---|
Normal Concentrations |
---|
| |
Blood | Detected and Quantified | 1.02 +/- 0.33 uM | Adult (>18 years old) | Both | Normal | | details |
|
---|
Abnormal Concentrations |
---|
| Not Available |
---|
Predicted Concentrations |
---|
| |
Blood | 0.000 umol/mmol creatinine | Adult (>18 years old) | Both | Normal | Predicted based on drug qualities |
|
---|
Associated Disorders and Diseases |
---|
Disease References | None |
---|
Associated OMIM IDs | None |
---|
External Links |
---|
DrugBank ID | DB00455 |
---|
Phenol Explorer Compound ID | Not Available |
---|
FooDB ID | FDB023577 |
---|
KNApSAcK ID | Not Available |
---|
Chemspider ID | 3820 |
---|
KEGG Compound ID | C06818 |
---|
BioCyc ID | Not Available |
---|
BiGG ID | Not Available |
---|
Wikipedia Link | Loratadine |
---|
METLIN ID | 1021 |
---|
PubChem Compound | 3957 |
---|
PDB ID | Not Available |
---|
ChEBI ID | 6538 |
---|
Food Biomarker Ontology | Not Available |
---|
VMH ID | Not Available |
---|
MarkerDB ID | Not Available |
---|
Good Scents ID | Not Available |
---|
References |
---|
Synthesis Reference | Vilani, Frank J. Antihistaminic 11-(4-piperidylidene)-5H-benzo-(5,6)-cyclohepta-[1,2-b]-pyridines. U.S. (1981), 4 pp. CODEN: USXXAM US 4282233 19810804 CAN 95:203761 AN 1981:603761 |
---|
Material Safety Data Sheet (MSDS) | Download (PDF) |
---|
General References | - Simons FE, Silver NA, Gu X, Simons KJ: Clinical pharmacology of H1-antihistamines in the skin. J Allergy Clin Immunol. 2002 Nov;110(5):777-83. [PubMed:12417888 ]
- Green LB, Hornyak JE, Hurvitz EA: Amantadine in pediatric patients with traumatic brain injury: a retrospective, case-controlled study. Am J Phys Med Rehabil. 2004 Dec;83(12):893-7. [PubMed:15624567 ]
- Purohit A, Melac M, Pauli G, Frossard N: Comparative activity of cetirizine and desloratadine on histamine-induced wheal-and-flare responses during 24 hours. Ann Allergy Asthma Immunol. 2004 Jun;92(6):635-40. [PubMed:15237765 ]
- Kornhuber J, Quack G, Danysz W, Jellinger K, Danielczyk W, Gsell W, Riederer P: Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology. 1995 Jul;34(7):713-21. [PubMed:8532138 ]
- Deep P, Dagher A, Sadikot A, Gjedde A, Cumming P: Stimulation of dopa decarboxylase activity in striatum of healthy human brain secondary to NMDA receptor antagonism with a low dose of amantadine. Synapse. 1999 Dec 15;34(4):313-8. [PubMed:10529725 ]
- Strong DK, Eisenstat DD, Bryson SM, Sitar DS, Arbus GS: Amantadine neurotoxicity in a pediatric patient with renal insufficiency. DICP. 1991 Nov;25(11):1175-7. [PubMed:1763530 ]
- Ramboer I, Bumtbacea R, Lazarescu D, Radu JR: Cetirizine and loratadine: a comparison using the ED50 in skin reactions. J Int Med Res. 2000 Mar-Apr;28(2):69-77. [PubMed:10898119 ]
- Shiller AD, Burke DT, Kim HJ, Calvanio R, Dechman KG, Santini C: Treatment with amantadine potentiated motor learning in a patient with traumatic brain injury of 15 years' duration. Brain Inj. 1999 Sep;13(9):715-21. [PubMed:10507453 ]
- Wilkinson R, Meythaler JM, Guin-Renfroe S: Neuroleptic malignant syndrome induced by haloperidol following traumatic brain injury. Brain Inj. 1999 Dec;13(12):1025-31. [PubMed:10628507 ]
|
---|